Fredun Pharmaceuticals Ltd (BSE: 539730) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,527 Cr, it ranks #1,134 by market cap among the 6,197 Indian listed companies on FinBizNet, and #35 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,503.00 (as of 16 Nov 2026), the share price is 9.7% below its 52-week high of ₹1,665.00 and 25.8% above its 52-week low of ₹1,195.20. The share price is up 238.8% over one year and up 67.4% over three months.
| Current Price | ₹1,503.00 |
|---|---|
| Market Cap | ₹2,527 Cr |
| BSE Code | 539730 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 74.7 |
| Return on Equity | 15.55% |
| Return on Assets | 9.14% |
| 52-Week Range | ₹1,195.20 – ₹1,665.00 |
| 1-Year Price Change | +238.8% |
| 3-Month Price Change | +67.4% |
| Beta (1Y) | 0.47 |
| Dividend Yield | 0.02% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.fredungroup.com |
Delivery averaged 46.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressant, antifungal, antihistamines/antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators and anti-asthma drugs, calcium tablets, cardiovascular, diuretic, impotence drugs, laxative, and appetite stimulant with multivitamins. It also provides surgical products, such as IV fluids and cannula, disposable syringes, infusion sets, surgical gloves and
1. Pharmaceutical Formulations-This segment manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products. It also provides animal healthcare products, as well as allopathic formulations and on field diagnostic kits.
1. Pharmaceutical and Healthcare-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Fredun Pharmaceuticals Ltd | ₹2,527 Cr | 74.7 | 15.55% | — | +238.8% |
Listed by market capitalisation. Ratios are shown for context only.
Fredun Pharmaceuticals Ltd is trading at ₹1,503.00, with a market capitalisation of ₹2,527 Cr.
Fredun Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Fredun Pharmaceuticals Ltd has a P/E of 74.7 and a return on equity of 15.55%.
Fredun Pharmaceuticals Ltd is listed on the BSE under the scrip code 539730.
Fredun Pharmaceuticals Ltd's share price is up 238.8% over one year and up 67.4% over three months. Its 52-week range is ₹1,195.20 to ₹1,665.00.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.